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ABSTRACT
Introduction: This article is part of the series “How to Prepare a Systematic Review (SR) of Economic
Evaluations (EE) for Informing Evidence-based Healthcare Decisions” in which a five-step-approach for
conducting a SR of EE is proposed.
Areas covered: This paper explains the data extraction process, the risk of bias assessment and the
transferability of EEs by means of a narrative review and expert opinion. SRs play a critical role in
determining the comparative cost-effectiveness of healthcare interventions. It is important to determine
the risk of bias and the transferability of an EE.
Expert commentary: Over the past decade, several criteria lists have been developed. This article aims
to provide recommendations on these criteria lists based on the thoroughness of development,
feasibility, overall quality, recommendations of leading organizations, and widespread use.
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1. Introduction
In this article, which focuses on Step 3 of the overall frame-
work (see Figure 1 [1]), attention will be paid to data extrac-
tion, risk of bias assessment, and transferability when
preparing a systematic literature review of economic evalua-
tions (SR-EEs). Moreover, the article is also perfectly readable
as a stand-alone read.
In 2003, the Appraisal of Guidelines for Research and
Evaluation (AGREE) collaboration issued an instrument for
evaluating the process of developing clinical practice guide-
lines (CPGs) and the quality of reporting [2]. Updated in 2010
to AGREE II [3], this instrument consists of several domains, of
which ‘rigor of development’ and ‘applicability’ are of impor-
tance to this article. These two domains reveal that recom-
mendations need to consider (1) health benefits, side effects,
and risks (domain 3, item 11) and (2) the potential resource
implications of applying the recommendations or, in other
words, ‘what does it cost when a certain recommendation is
implemented?’ (domain 5, item 20) [4]. This means that CPGs
need to consider not only the potential effectiveness of
health-care interventions but also their cost–effectiveness, as
well as their overall impact on budget.
When creating or updating CPGs, SRs play a critical role in
determining the comparative cost–effectiveness of health-care
interventions, with the goal of creating an efficient health-care
system [5]. However, EEs are prone to several biases. Bias
occurs when there is a difference between the true value (in
the population) and the observed value (in the study) from
any cause other than sampling variability [6]. A bias can be
unintentional or intentional and can have either substantial or
little impact on the results of an EE [7]. In order to make
optimum policy decisions, it is important to determine the
risk of bias in an EE [7]. For example, EEs may have a perspec-
tive that is too narrow or may fail to incorporate important
costs. In addition, one should be aware of the opportunity
costs from decisions based on poor-quality EEs (i.e. misleading
study findings, lack of transparency, and clarity in reporting
[8]). Hence, in the past decades, several criteria lists have been
developed to assess the risk of bias in EEs and to evaluate the
transferability of EE. These lists are important tools that help to
interpret and compare individual studies. However, due to the
number and availability of all these tools, it can be difficult to
make a careful selection.
Full EEs can differ in a variety of aspects, and all aspects can
affect the quality of the evaluation and consequently bias
results. The term ‘full EE’ refers to the comparative analysis
of alternative courses of action in terms of both costs
(resource use) and consequences (outcomes and effects) [5].
Basically, there are two approaches to performing an EE study
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[7]: (1) an EE which is piggy-backed onto a clinical effective-
ness study (e.g. a randomized controlled trial or observational
study), often called a trial-based EE; and (2) a model-based EE,
in which data from a wide range of sources (randomized
controlled trials, observational studies, trial-based EEs, and
other literature or reports) are combined using an economic
model. Both are complementary to each other [5]. For a
model-based EE, it is important that the external validation
of the results, the key structural assumptions, and the data
sources and derivation of the input data used in the model are
well described. This way, potential policymakers or CPG devel-
opers are able to incorporate the strengths and limitations of
the EE in their evaluation of the evidence [9]. It is important to
keep in mind that the quality of EEs can be only as good as
the quality of the trials on which they are based [9]. This holds
true for both model-based EE and trial-based EE. As the field
of effectiveness studies is relatively old in comparison with the
field of EEs, methodological issues (i.e. the Cochrane collabora-
tion’s tool for assessing the risk of bias [10]), reporting stan-
dards (i.e. the consolidated standards of reporting trials
(CONSORT) statement [11] and the strengthening the reporting
of observational studies in epidemiology (STROBE) statement
[12]), and the grading of evidence methods (i.e. the Grading of
Recommendations Assessment, Development, and Evaluation
(GRADE) method for determining the quality of a body of
evidence [13]) have been established and are regularly being
used and recognized in the development of CPGs for SRs. For
example, as in clinical studies, biases in (full) EEs can occur as a
result of poor methodological quality, which can impact the
validity of the results in terms of generalizability or transfer-
ability [7]. Evers et al. [7] have identified some methodological
biases (so-called ‘pretrial and during trial biases’), e.g. biases
that occur as a result of a narrow perspective, inefficient com-
parator, cost measurement omission, or inappropriate discount-
ing. In addition, they have identified some after-trial biases such
as reporting and dissemination bias. Although these biases are
thought of more in relation to trial-based EE, most of them are
also applicable to model-based EE.
Therefore, this article will focus only on risk of bias and
transferability checklists specifically tailored for the critical
appraisal of EEs. SR-EEs can be categorized roughly into
three groups: (1) multipurpose reviews, (2) reviews for inform-
ing the development of CPGs, and (3) reviews for developing
decision analytic models. Both multipurpose SR-EEs and SR-
EEs for guideline development aim to synthesize and critically
appraise existing EEs of a health-care intervention or disease
area in order to inform policy decisions [1,14]. The guidance in
this article covers only the first two types of SR categories.
Accordingly, this article is aimed mainly at CPG developers
although the checklists can also aid others who want to pre-
pare SR-EEs, like health technology assessment (HTA) research-
ers, systematic reviewers, and students, as they seek to
identify the different steps, important key sources, and prac-
tical information to gain basic knowledge on this topic.
To be sure all relevant data of the included studies have
been collected, it is important to develop a data extraction
sheet for more systematic data collection. A data extraction
sheet is an organized table in which all relevant items which
need to be extracted for the review are listed; this needs to be
completed for every study in order to collect data system-
atically. The inclusion of items depends on the research ques-
tion or study objective and on the study design and outcomes
predefined in the study protocol (see Step 1.3 of the overall
framework in Van Mastrigt et al. [1]).
Accordingly, this article will first discuss the data extraction
sheet and then present an overview of the methods most
commonly used to assess the risk of bias and the transferabil-
ity of EEs.
2. Step 3.1 of the overall framework: data extraction
This step entails extracting all relevant data from the included
studies. For every SR-EE, a tailored data extraction sheet needs
to be developed. Which items are included depends on the
research question or study objective and on the study design
and outcomes predefined in the study protocol (see Step 1:
Figure 1. Overview of 5-step approach for preparing a systematic review of economic evaluations of healthcare interventions.
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‘Initiating SR-EEs’ of the overall framework). Consideration of
the care pathway can be helpful in structuring the data extrac-
tion [15]. In addition, the risk of bias in the included studies
needs to be appraised, in order to assess the possible impact
of bias on the results of SRs (Step 3.2). Excel (Microsoft Office,
Microsoft Corporation, Washinton) can be used for the digital
registration of items. It is highly recommended that the extrac-
tion sheet be piloted for user-friendliness and completeness,
using a few sample studies [15,16]. Then, if needed, the data
extraction form can be adapted before starting data extraction
of all studies. For Step 3.1, the data extraction of study char-
acteristics, methods, and outcomes, it is important to simply
report the findings as reported by the authors of the study
and not draw any conclusions from them. This is in contrast
with Step 3.2, the risk of bias assessment, in which a critical
appraisal of the studies is necessary for answering all
questions.
There are several example of data extraction forms available
from the literature [15–17], containing many common items.
These items can be classified in two groups. First, the general
study characteristics: these are, for instance, author, year of pub-
lication, type of intervention, control treatment, eligibility criteria,
study perspective, type of EE, and analytic approach (trial based
versus model based). Second, the study methods and outcomes:
these include resource use, costs, effects, measurement, valua-
tion methods, incremental cost–effectiveness ratios, uncertainty
analyses, sensitivity analysis, and conclusions. Based on our
experience, we recommend including all relevant items from
the list in Table 1 in the initial data extraction. If one is particularly
interested inmodel-based EEs, one could extend this list with the
external validation of the results, the key structural assumptions,
and data sources and derivation of the input data used in the
model. Using a picklist is recommended for choosing the differ-
ent answers. Furthermore, in order to facilitate the interpretation
of the results, a disaggregated presentation of the results, as well
as incremental cost–effectiveness ratios, is highly recommended
[15]. When presenting information derived from the data extrac-
tion, in some cases it may bemore appealing to present in a table
than others. Table 2 and Table 3 provide an example of how to
present the general study characteristics and the economic evi-
dence. In this study of De Kinderen et al. [18], a ketogenic diet is
compared with care as usual to reduce epileptic seizures in
children with intractable epilepsy.
3. Step 3.2 of the overall framework: risk of bias
assessment
This step focuses on the risk of bias assessment for the studies
included in SR-EEs. Although the risk of bias in EEs is equally
important in CPG development and multipurpose reviews,
differences might occur in the type of EEs included. In general,
full EEs are recommended as being the most valid way to
conduct an EE. Accordingly, we would like to stress that full
EEs should be preferred over partial EEs at all times. However,
in CPG development and/or in the absence of full EEs, one
might be interested in partial EEs (e.g. costs analyses). Partial
EEs may represent important intermediate stages in our
understanding of the costs and consequences of health ser-
vices programs and therefore might be convenient, e.g. in
(early) CPG development [5]. Hence, both full and partial EEs
will be discussed separately, with the difference that partial
EEs will be discussed only in relation to CPG development.
In addition, although the risk of bias assessment and the
way of reporting the results of EEs might seem like two dis-
tinct topics, in practice both topics are intertwined and diffi-
cult to differentiate from one another. For example, in order
for a flawlessly conducted EE to be perceived as having ’low
risk of bias,’ it should be reported in a transparent and com-
prehensive way. While this article will focus on the risk of bias
assessment of EEs, it is important to keep this in mind when
reading the rest of the article. Specifically in order to assess
the reporting quality of an EE, the International Society of
Pharmacoeconomics and Outcomes Research (ISPOR) task-
force has developed the Consolidated Health Economic
Evaluation Reporting Standards, in which recommendations
are made to optimize the reporting of health EEs for all
types of EE derived by either trial- or model-based EE [8].
3.1. Risk of bias assessment for multipurpose SR-EEs
As full EEs are considered to be the best strategy to answer
efficiency questions [5], most checklists focus solely on full EEs.
Over the past decades, several criteria checklists for the risk of bias
assessment of full EEs have been constructed. A recent SR by
Walker et al. [19] identified 10 checklists and criteria lists published
between 1992 and 2011. In addition to the studies identified by
Walker et al., we identified three additional studies: the checklists
of Sculpher et al. [20], Philips et al. [21], and Caro et al. [22] (ISPOR
checklist). An assessment of these checklists was made based on
the purpose of the development, thoroughness of the develop-
ment process, number of criteria checklists, operationalization of
the questions, assessment instructions, time to complete, whether
the checklist includes an overall quality score, and the number of
references (providing us with an indication of its frequency of use).
The full overview can be found in online supplementary material I.
The British medical journal (BMJ) checklist [23] and the consensus
on health economics criteria checklist (CHEC)-extended checklist,
which is an extension of the original CHEC checklist to include a
question regarding model-based EE [24–26], are commonly con-
sidered to have more scrutiny than most other lists [16].
Accordingly, the Cochrane collaboration recommends using one
of these two checklists to assess the risk of bias of full trial-based
EEs conducted alongside single-effectiveness studies. In addition,
the BMJ checklist is also recommended by the Campbell &
Cochrane Economics Methods Group for use in SRs. However, if
the scope of the critical review of EEs encompasses relevant
economic modeling studies, then assessments of the risk of bias
of such studies will need to be informed by a different checklist, as
the BMJ checklist and the CHEC-extended checklist are relevant
but not sufficient for modeling studies [16]. Both the Cochrane
collaboration and the National Institute for Health and Care
Excellence (NICE) recommend using the Philips checklist to assess
modeling studies [27]. However, as the Philips checklist contains a
relatively large amount of criteria, using this checklist may not be
feasible if one is interested specifically in a large number of model-
based EEs. In cases where one is specifically interested in model-
based EE and if the expected number of included studies is low
(e.g. <10 studies; pragmatic decision), the Philips checklist [21]
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Table 1. Items and explanation for the data extraction of economic evidence.
Number Type of items Explanation
Checklist completed by State the name of person who has filled out the data extraction sheet.
General study characteristics
1 First author and year of publication Report: First author, title, journal name, publication date, volume, issue, page numbers,
and link to the publication.
2 Sources of funding Report: The source of funding cited in the article: write ‘stated’ or ‘not stated’ and specify.
If any, give name(s) of organization or corporation. Specify if possible the source type
(public research funds, NGO, government, academic/university, health-care industry, or
other).
3 Competing interests Competing interests: write “stated” or “not stated” and specify if any.
4 Publication type Describe type of publicationb (journal paper and HTA report)
5 Setting List the country/countries, setting, and/or locations for economic evaluation.
6 Patient characteristics Summarize inclusion and exclusion criteria (eligibility criteria/demographics).
7 Type of intervention Describe the experimental treatment (service, program).
8 Control treatment Describe the control treatment (service, program).
9 Eligibility criteria Describe the eligible population and the population used for effect/cost data.
10 Study perspective State the viewpoint of the analysis (society, health care, insurer, care provider, patient, and
family).
11 Type of EEs Specify the form of economic evaluation being used (e.g. CEA, CUA, CBA, and CCA).
12 Analytic approach Describe the analytic approach: trial based or model based.
Methods and outcomes of economic evaluations
13 Time frame of the analysis (time horizon) State the time horizon for both costs and benefits.
14 Discount rate Was discounting performed?
15 Discount rate for costs What was the discount rate for the costs(s)?
16 Discount rate for effects What was the discount rate for the effects(s)? (i.e. the rate used to account for different
timing of costs and effects)
17 Inflation rate Was adjustment for inflation performed if unit costs stemmed from different years?
18 Reference year What was the reference year of the analysis?
19 If model based Detail any model used (Markov, Decision Tree, and Discrete Event Simulation)c
20 Type and category of costs Describe the different cost types and categories used (e.g. direct in health care, indirect
health care, and intangible costs).
21 Data source of resource use Describe the data for resource use (e.g. clinical trials, administrative data, clinical
databases, medical records, and published literature).
22 Methods for identifying resource use Describe the methods used to identify resource use (questionnaire, survey, cost dairies,
expert consultation, and formal consensus methods).
Assumptions of the measurement of resources Describe, for instance, method of imputation when incomplete measurement occurred.
22 Costs (in reported currency or in converted currency) Present relevant costs and outcomes in both disaggregated and aggregated form (with
confidence intervals and measures of significance).
24 Methods used to calculate unit costs Describe the methods used to identify relevant unit costs (guidelines, own cost price
calculations, and literature).
25 Costsa Present relevant costs in disaggregated and aggregated form (with confidence intervals
and measures of significance).
27 Data source of effects Specify where utilities or benefits came from (literature values and elicited in the study).
28 Methods of measurement of effects Specify source of effectiveness estimates (stated WTP, revealed WTP, and conjoint analysis).
29 Methods of valuation of effects Specify methods of valuation of effects (indirect or direct measurement).
30 Effectsa Present relevant effects (utilities, [health] benefits, and outcomes) in disaggregated and
aggregated form (with confidence intervals and measures of significance).
31 Incremental cost–effectiveness ratios State the summary measure of benefit for CUA (e.g. QALY or DALY).
32 Analyses of uncertainty (e.g. sensitivity analyses) Describe the analyses of uncertainty (e.g. statistical comparison, bootstrapping, sensitivity
analysis [one-way, multiway], threshold analysis, analysis of extremes, and best/worst
case analysis) and probabilistic sensitivity analysis.
34 Outcome(s) of analyses of sensitivity analyses
35 Authors’ conclusions Report the conclusions of the authors
aWhen reporting the study outcomes, it is preferred to report the degree of uncertainty; therefore, in addition to reporting the mean (or median), a standard
deviation (or range) should be reported [5].
bDuplicate publications of the same study need to be linked together.
cCheck for details: Philips et al. [21].
CEA: cost–effectiveness analyses; CUA: cost–utility analyses; CCA: cost–consequence analyses; CBA: cost–benefit analyses; EEs: economic evaluations; QALY: quality-
adjusted life year; NOG: Non-governmental organization; HTA: Health Technology Assessment; WTP: Willingness to pay; DALY: Disability adjusted life years.
Table 2. Example of data extraction for multipurpose review: general, RCT-related, and economic characteristics.
Author Year Disease N Intervention
Trial- or model-
based EE
Comparator
(s)
Outcome
measure(s) Perspective
Intervention
cost-effective
De Kinderen
et al.
2016 Refractory
epilepsy
48 Ketogenic
diet
Trial-based EE Care as
usual
QALY gain Health-care
perspective
No, based on cost per
QALY
Etc.
Etc.
EE: economic evaluations; QALY: quality-adjusted life year; RCT: randomized controlled trial.
Based on De Kinderen et al. 2016.
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could be used. In cases where the number of included model-
based EEs is high (e.g. >10 studies; pragmatic decision), consider-
ing the feasibility and thoroughness of the developmental pro-
cess, the ISPOR checklist is likely to bemore practical for reviewing
purposes [22].
In Table 4, an example is provided of how one can con-
duct the appraisal of a study using the CHEC-extended
checklist. The appraisal process in this example was guided
by assessment instructions specifically designed for the CHEC
checklist. Again, the study of De Kinderen et al. [18] was used
as an example. For most checklists, such instructions are
available and make the appraisal process more
straightforward.
3.2. Risk of bias assessment in SR-EEs for CPG
development
The GRADE approach has been developed to rate the conﬁ-
dence in effect estimates (quality of evidence) for clinical out-
comes and is often used and highly recommended in CPG
development [13]. This approach was recently extended to
include the quality of economic evidence (both for partial
and full EEs). In general, the GRADE recommends that impor-
tant differences in resource use should be included along with
other important outcomes in the evidence proﬁles and sum-
mary of findings tables. In this process, four key steps have
been identified: (1) identify items of resource use that may
differ among alternative management strategies and that are
Table 3. Example of data extraction for multipurpose review: cost–effectiveness results.
Author Year Disease Main outcome ICER/ICUR
De Kinderen
et al.
2016 Refractory
epilepsy
The results show that the KD reduces seizure frequency. The study
did not ﬁnd any improvements in quality of life and, therefore,
unfavorable cost per QALY ratios resulted.
1) CEA: €18,422.21 per responder; 2) CUA: not presented
but 5% probability of being cost-effective at the ceiling
ratio of €50,000 per QALY
Etc.
Etc.
KD: ketogenic diet; CAU: care as usual; ICER: incremental cost–effectiveness ratio; ICUR: incremental cost–utility ratio; QALY: quality-adjusted life year; CEA: cost–
effectiveness analyses; CUA: Cost-utility analysis; RCT: randomized controlled trial.
Based on De Kinderen et al. 2016.
Table 4. Example of critical appraisal of the quality of the economic evaluation using the CHEC checklist.
CHEC-extended items
(Evers et al. 2005; Odnoletkova et al. 2014)
De Kinderen et al.
(2015)
1 Is the study population clearly described? Yes (see in method section, study population and sample size
section, and result section; Table 2)
2 Are competing alternatives clearly described? Yes, sufficient details provided on usual care group vs. ketogenic
diet group.
3 Is a well-defined research question posed in answerable form? Yes, last sentence of the introduction.
4 Is the economic study design appropriate to the stated objective? Yes, an appropriate study design is used. The economic study
design is a full economic evaluation (comparison of costs and
effects of two interventions).
5 Are the structural assumptions and the validation methods of the
model properly reported?
NA (trial-based EE)
6 Is the chosen time horizon appropriate in order to include relevant
costs and consequences?
No, a 3-month time horizon is too short; for a societal perspective, a
time frame of at least 1 year is generally accepted.
7 Is the actual perspective chosen appropriate? Yes, the societal perspective is preferred in The Netherlands.
8 Are all important and relevant costs for each alternative identified? Yes (see method section: protocol-driven intervention costs, health-
care costs, patient and family costs, and productivity costs are
included.
9 Are all costs measured appropriately in physical units? Yes, cost diaries were used.
10 Are costs valued appropriately? Yes, sources of valuation including the reference year mentioned.
11 Are all important and relevant outcomes for each alternative
identified?
Yes, outcomes are relevant, and they fit the research question and
perspective.
12 Are all outcomes measured appropriately? Yes, measurement instruments are relevant and described.
13 Are outcomes valued appropriately? Yes (see method section) EQ-5D using a Dutch utility-tariff was
used.
14 Is an appropriate incremental analysis of costs and outcomes of
alternatives performed?
Yes, ICER/ICUR is calculated.
15 Are all future costs and outcomes discounted appropriately? NA when using a time frame for analyses of less than 1 year,
discounting is not needed.
16 Are all important variables, whose values are uncertain,
appropriately subjected to sensitivity analysis?
Suboptimal, not all parameters.
17 Do the conclusions follow from the data reported? Yes, conclusions are supported by the data.
18 Does the study discuss the generalizability of the results to other
settings and patient/client groups?
Yes, mentioned and (briefly) discussed in the discussion section of
the article.
19 Does the article/report indicate that there is no potential conflict of
interest of study researcher(s) and funder(s)?
Yes, the authors report having no conflict of interest.
20 Are ethical and distributional issues discussed appropriately? Yes, the study was approved by the Medical Ethics Committee of
Maastricht University.
Based on De Kinderen et al. 2016.
NA: not applicable; EE: economic evaluation; ICER: incremental cost–effectiveness ratio; ICUR: incremental cost–utility ratio; CHEC: consensus on health economics
criteria checklist; EQ-5D: EuroQol 5-dimensions.
EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH 727
potentially important to patients and decision-makers; (2) find
evidence for the differences in resource use between the
options being compared; (3) rate the conﬁdence in estimates
of effect; and (4) if the evidence proﬁle and summary of
findings tables are being developed to inform recommenda-
tions in a speciﬁc setting, value the resource use in terms of
costs for the speciﬁc setting for which recommendations are
being made [28]. Resource use and the cost of treatments are
included in the summary of findings tables. The cost–effec-
tiveness estimates are included in the evidence profiles as
background information. In this way, it is possible to include
the results of partial EEs (e.g. cost analyses) in a systematic
way in the GRADE approach when developing guidelines.
However, the GRADE recommends excluding model-based EE
as they are often based on trials which could lead to double
counting [28]. Furthermore, the GRADE recommends that the
conﬁdence in effect estimates for each important or critical
economic outcome should be appraised explicitly, using the
same criteria as for health outcomes, so evidence derived from
randomized trials starts at high quality, and evidence derived
from observational studies starts at low quality [28]. In addi-
tion to integrating economic evidence in CPG development,
using the previously described risk of bias checklist is comple-
mentary to the GRADE approach in assisting CPG developers
in their deliberations [29]. Accordingly, to overcome the lack
of compatibility with model-based EEs in the GRADE
approach, the NICE has developed a checklist, specifically
developed for the UK, composed of items from the CHEC
and the Philips checklists. This composite checklist consists
of 10 items regarding applicability and 12 items on study
limitations (see Appendix H of the NICE Guidelines Manual
[27]). One should be aware, however, that this list is based
solely on expert opinion.
Overall, it can be concluded that when using the GRADE
approach in developing CPGs, there is a way to systematically
incorporate economic evidence from a partial EE. For further
reading on this topic, we recommend checking the GRADE
website (http://www.gradeworkinggroup.org/). In addition to
incorporating economic evidence into CPG development, it is
important to perform a complementary assessment on study
applicability and the possible limitations for CPG using the
NICE checklist [27]. As the NICE checklist is specifically
designed for the UK, some minor adjustments are necessary
to use it across jurisdictions, paying attention to such factors
as the preferred perspective, the discount rate, or the pre-
ferred source of preference data.
4. Step 3.3 of the overall framework: transferability
assessment of economic evaluations (for both
multipurpose SR-EEs and SR-EEs for guideline
development)
When conducting an SR to identify EEs which are applicable to
a specific country or setting, or when developing a CPG and
one is interested in cost–effectiveness or cost–utility data, it is
important to determine the transferability and generalizability
of such studies. Transferability is referred to as the extent to
which the results of a study hold true for a different popula-
tion or setting [30]. For example, results derived from a study
conducted in a developed country will not be representative
for use in a developing country. Generalizability is defined as
the extent to which the results of a study can be generalized
to the population from which the sample was drawn [30].
Although theoretically there is a clear difference between
both concepts, they are often used interchangeably. To deter-
mine the transferability of a study, it is important to know
what country-specific pharmacoeconomic guidelines exist and
what the differences are between countries. To obtain infor-
mation regarding country-specific pharmacoeconomic guide-
lines, the ISPOR has developed a comparative table of 33
countries, including key features for several (mostly European
& American) countries (http://www.ispor.org/peguidelines/
index.asp). For example, one should pay attention to the tariff
used to derive quality-adjusted life years, which is one of the
key transferability issues within cost–utility analyses, or to the
perspective used and to the referred discount rates.
However, solely having the key features available for a coun-
try (or for a local setting) is not enough for most researchers to
assess the transferability of an EE. Accordingly, as is the case for
the risk of bias assessment, several instruments exist to evaluate
the transferability of an EE (see online supplementary material II).
In an SR, Goeree et al. [31] identified seven checklists for
determining the transferability of EEs. Based on the same
criteria as the risk of bias checklists, an assessment of these
checklists and the full overview can be found in online sup-
plementary material II. In comparison to the risk of bias check-
lists, these checklists focus mainly on decision-making and on
the implementation of study results in a particular setting. The
checklist of Welte et al. was found to be a convenient list
because it has clear cutoff points and can be used for the
assessment of both trial- and model-based EEs. It has been
applied successfully in the past [32], and the model has been
tested extensively by Knies et al. [30]. The Welte checklist [33]
consists of three general knockout criteria which need to be
considered before proceeding to 14 specific knockout criteria
(see Table 5). The Drummond (2009) checklist is largely based
on the Welte checklist, and the two checklists differ only
slightly in their application and content. Accordingly, overall,
using the Welte checklist can be recommended. In addition,
one should be aware that it is important to discuss the trans-
ferability of a particular study with clinicians as clinical practice
might vary between countries.
In Table 5, an example is provided of how one may conduct
the appraisal of a study using the Welte checklist. In this
example, results of the study of De Kinderen et al. [18] are
hypothetically transferred from The Netherlands to the UK
setting. As can be seen from the example, the difference in
perspective between the UK and The Netherlands may lead to
the cost–effectiveness ratio being either too high or too low.
In this case, one should recalculate the cost–effectiveness ratio
excluding costs outside the health-care setting.
4.1. Usability of the different checklists for both
multipurpose SR-EEs and SR-EEs for guideline
development
We provide general recommendations regarding which
checklist to use for assessing risk of bias and transferability.
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These recommendations are based on a balance of the
various aspects as described in the previous section.
However, to determine what checklist fits best, several
other study-specific characteristics determine the actual
decision of which list or lists to select. These are, for
instance, the time available for the review, the experience
of the reviewers, the audience of the SR, and the purpose
the checklist is designed for in relation to the aim of the
review. In addition, the number of items and the time
needed to complete a checklist are important factors in
determining the applicability of a checklist. For example,
the checklist of Philips [21] is often referred to by CRD as
an instrument for appraising the risk of bias within modeling
studies [15] although it is often ignored, due to the large
number of criteria (61 items). Accordingly, it is important to
look at feasibility when choosing the most appropriate
checklist(s).
Moreover, one should be aware that raters are a relevant
source of variability [34]; this highlights the importance of
multiple raters (at least two) so that discrepancies can be
resolved through consensus meetings between raters. In prac-
tice, this implies that, in addition to having multiple raters, a
few studies (i.e. two or three) should be used to pilot the
assessment between multiple raters, after which discrepancies
should be discussed between raters to ensure a more uniform
assessment strategy (see also Step 2.4, Thielen et al. [35] and
Mastrigt et al. [1]).
5. Expert commentary
The starting point for the data extraction, risk of bias, and
transferability assessment phase is the development of the
data extraction sheet. This serves as a basis for collecting
data from all the articles included under review. For conve-
nience, one should include the selected risk of bias and trans-
ferability checklists in the data extraction sheet.
Next, as shown above, several checklists exist for assessing
a variety of factors influencing the validity of study results
within a particular setting. Accordingly, depending on the
purpose of the review, different recommendations can be
made. When one is interested in trial-based EEs, taking into
account the thoroughness of the developmental process, the
user friendliness, feasibility, and purpose of each checklist, the
CHEC-extended [24] and the BMJ checklists [23] are most
convenient to use. However, these checklists are insufficient
when one is also interested in appraising model-based EEs.
Therefore, although its length makes it cumbersome to apply
to a large number of studies, the Philips checklist [21] should
be considered. However, it should be noted that in current
literature, there seems to be a lack of consensus regarding the
best instrument for assessing the risk of bias of model-
based EEs.
As stated above, all currently available checklists focus on
full EEs, as full EEs are considered to deliver a high quality of
evidence. However, especially in CPG, other factors might be
considered in addition to cost–effectiveness data, such as the
financial implications of the respective treatment. In this case,
the use of a partial EE in an SR might be justified. The GRADETa
bl
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approach came up with a method of incorporating economic
evidence when developing CPG, but this method is not suita-
ble for model-based EEs. In addition, the GRADE approach
focuses on the estimated use of resources, which is only part
of a (full) economic evaluation. Therefore, we would recom-
mend performing a complementary assessment on study
applicability and the limitations for CPG using the NICE check-
list [27].
Looking at transferability, several checklists have been
identified, of which the Welte checklist [33] has raised the
most attention, likely due to the relative ease of application.
In addition, the Welte checklist has been thoroughly examined
[30], and the checklist of Drummond et al. [36] is based on the
work of Welte et al. [33]. If one is particularly interested in
assessing the applicability of HTAs to resource allocation deci-
sions, the Grutters checklist [37] might be a suitable option
(see online supplementary material II). One should keep in
mind that, when incorporating economic evidence in a CPG,
a transferability check should always be performed.
A summary of the recommendations made in this article
can be found in Table 6.
The field of risk of bias assessment is developing quickly,
resulting in numerous different checklists with different objec-
tives. This article attempts to highlight the most important
checklist currently available, but one should be aware of other
checklists in this field. For example, although the product of
their research is not defined as a checklist, Evers et al. [7]
provide a list of risks of bias in trial-based EEs. Building on
this and several other articles such as the Philips checklist [21],
Adarkwah et al. [38] have developed the Bias in Economic
Evaluation checklist (ECOBIAS), which is a checklist to deter-
mine the risk of bias in EEs. However, ECOBIAS is directed
more toward model-based EEs. The checklist is aimed at pro-
viding a full overview of the biases that could occur in model-
and trial-based EEs and includes a total of 22 biases, of which
11 are specific for model-based economic studies.
Furthermore, for model developers or users of decision mod-
els, Vemer et al. [39] have developed a checklist, called
‘Assessment of the Validation Status of Health-Economic deci-
sion models (AdViSHE),’ which provides model users with a
structured view into the validation status of the model,
according to a consensus on what good model validation
entails. AdViSHE may provide guidance towards additional
validation of a model. However, when preparing an SR, using
these checklists as add-ons to other risk of bias or transfer-
ability instruments will require a good understanding of EEs
and will make the risk of bias assessment a time-consuming
exercise.
6. Five-year view
Currently, data extraction in SR-EEs is done in several ways,
and every author focuses on (slightly) different aspects.
However, to improve the comparability of studies, there is a
need for a more uniform standard with regard to data extrac-
tion sheets.
At this point, numerous checklists have been developed
and applied within the field of SR and CPG development,
specifically focused on EE. However, future research might Ta
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further improve the risk of bias assessment of EEs. One impor-
tant topic would be the development and validation of a
single tool to assess and grade the risk of bias of both trial-
and model-based full EEs in health care. Such a risk of bias
assessment tool could make a substantial contribution to the
field of health economics, as it would assist end users of cost–
effectiveness studies to discriminate among the exploding
body of literature and help producers of such studies to
establish a clearer standard, potentially encouraging higher
quality and greater rigor [19]. However, to achieve the neces-
sary level of acceptance and use, the new tool must demon-
strate validity and reliability [19]. Accordingly, it is expected
that the GRADE approach will be adjusted to include model-
based EE.
A third important topic would be more uniform and wide-
spread guidance in the use of risk assessment instruments
(e.g. which checklist should be used in what situation). An
internationally supported protocol for the risk of bias assess-
ment of EEs would support comparative analyses between
reviews.
Fourth, there are only a limited number of studies looking
at the reliability and validity of the discussed checklists. Future
research should provide more insights into this matter.
The last topic would be to stress the need for increased
transparency within the field of health economic model devel-
opment, analysis, and reporting. This is particularly important for
model-based EEs, where it is often difficult to fully grasp all
important aspects of the model when reading only the accom-
panied article. By (freely) providing models (e.g. as online sup-
plementary material), one could increase the transparency, and
a more reliable risk of bias assessment could be conducted.
Key issues
● Currently, several checklists exist for assessing the risk of
bias and the transferability of EEs.
● All these checklists focus on full EEs. However, when devel-
oping CPG, one might be forced to use a partial EE in
resource allocation decisions. For this, the GRADE approach
is highly recommended. In addition, it is important to per-
form a complementary assessment on study applicability
and limitations using the NICE checklist [28].
● There is a lack of consensus regarding the best instrument
for assessing the risk of bias within a model-based EE. Of
the currently available checklists, the Philips checklist [21] is
recommended when it is deemed feasible.
● The checklist of Welte et al. [33] should be used when
determining transferability.
● There is a need to standardize the methods for data-extrac-
tion sheet development, use and filling in for EEs.
● There is a need for more uniform and widespread guidance
in the use of risk of bias checklists (e.g. which checklist
should be used in what situation). An internationally sup-
ported protocol for the risk of bias assessment of EEs would
support comparative analyses between reviews.
● Future research should focus on the development and
validation of a single tool to assess and grade the risk of
bias in both trial- and model-based full EEs in health care.
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